Agilex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Agilex

Property Description
Active ingredient Indometacin (Indomethacin)
Form Capsule, Extended-Release Capsule, Suspension (Liquid)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Systemic anti-inflammatory, analgesic, and antipyretic relief
Origin Synthetic

What Type of Medicine is Agilex? (Classification and Origin)

Agilex is a prescription medicinal product containing the active substance Indometacin, a potent synthetic compound classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its identity is rooted in its strong pharmacological action as a non-selective inhibitor of the cyclooxygenase (COX) enzyme. This mechanism directly blocks the body's synthesis of prostaglandins, which are critical mediators of inflammation, pain, and fever. Indometacin is clinically recognized for its powerful effect in modifying inflammatory responses, setting it apart from milder, general-purpose NSAIDs. This medicine works by helping to reduce the production of the natural substances that cause swelling and pain in the body.


Indometacin's Primary Purpose and Delivery Form

The primary purpose of Agilex is to provide powerful anti-inflammatory, analgesic, and antipyretic relief through systemic action, often used in scenarios where significant inflammation is the underlying issue. The drug is supplied in various oral dosage forms, including standard capsules, specialized extended-release capsules, and liquid suspension. The provision of a liquid suspension form is a differentiating factor, allowing flexibility in delivery. Indometacin has an established role in managing acute and chronic inflammatory states due to its potent inhibitory effects on the inflammatory cascade. Indometacin is a recognized, effective compound used for its ability to modify the body's generalized inflammatory response. This systemic route of administration ensures the active Indometacin is distributed widely, targeting internal inflammation and providing reliable therapeutic effects for widespread discomfort and swelling.

Regulatory References

  1. National Library of Medicine - MedlinePlus
  2. MedlinePlus

What side effects are possible with Agilex?

Possible Side Effects and Safety Information

This safety summary is based on the authoritative regulatory documentation for the medicine Agilus, which contains the active substance dantrolene sodium.

Adverse Reaction Scope

The most commonly reported adverse event associated with the use of this medicine is skeletal muscle weakness. This effect is related to the drug's intended action as a muscle relaxant.

Official regulatory sources note that the frequency of this specific side effect is not known, as there was insufficient data available to classify its commonness. Other side effects are generally classified as Not Known in terms of frequency but have been observed across various System Organ Classes.

System-Organ Classes Involved

Adverse reactions have been reported across several body systems, including:

  • Nervous system disorders (e.g., dizziness, headache, somnolence).
  • Gastrointestinal disorders (e.g., nausea, vomiting, abdominal pain).
  • Hepatobiliary disorders (e.g., liver function abnormalities, hepatitis, and in rare cases, fatal hepatic failure, typically observed with long-term oral use of the active substance).
  • Renal and urinary disorders (e.g., crystalluria).
  • Cardiac and Vascular disorders (e.g., cardiac failure, bradycardia, thrombophlebitis).

Safety-Related Restrictions and Limitations

Serious Adverse Reactions include, but are not limited to, respiratory failure, cardiac failure, and liver failure. Due to the high pH of the solution, extravascular injection must be strictly avoided as it can cause tissue necrosis. Intra-arterial injection must also be avoided due to the risk of vascular occlusion.

Population-Specific Safety Considerations

The potential for risks associated with one of the inactive ingredients, hydroxypropylbetadex, may be higher in patients with renal impairment. The safety of the active substance during pregnancy has not been established; it is known to cross the placenta. This medicine may also have a major influence on the ability to drive or use machinery, and such activities must be avoided due to the risk of skeletal muscle weakness, dizziness, and light-headedness, which may persist for up to 48 hours.

Overdose and Emergency Response

Agilex overdose requires immediate regulatory-mandated action due to the potential for severe, life-threatening outcomes. Officially documented signs of an overdose center on acute Gastrointestinal (GI) and Central Nervous System (CNS) disturbances. Manifestations include acute nausea, vomiting, stomach pain, diarrhea, intense headache, dizziness, mental confusion, and lethargy. More severe documented outcomes include convulsions, generalized seizures, and coma. The regulatory documents also specify risks of life-threatening events such as severe gastrointestinal bleeding, ulceration, perforation, and acute kidney damage (oliguria).

The official guidance mandates that any suspected overdose requires individuals to seek immediate medical help right away, which involves contacting emergency services or a Poison Help hotline.

No specific antidote is known for Indometacin overdose. The officially described management is symptomatic and supportive. Procedures listed in regulatory information include emptying the stomach by gastric lavage and administering activated charcoal. Due to the documented risk of delayed complications, including hemorrhage, prolonged close medical observation and follow-up care for several days are explicitly required.

Therapeutic Uses of Agilex

What Agilex Treats: Main Uses and Benefits

Agilex (Indometacin) is a medicine commonly used to provide supportive symptomatic relief across key domains characterized by significant inflammation and associated pain. Its application is relevant in clinical settings marked by heightened patient distress and where symptoms create noticeable interference with daily stability.

Managing Acute, Severe Inflammatory Attacks

This medicine is applied in contexts where additional support for symptom management is needed during episodes of sudden symptom escalation. It is most commonly used to address groups of symptoms that may become intense or disruptive, such as those related to acute gouty arthritis (gout). This supportive relief contributes to improved comfort during periods of heightened symptoms associated with acute or disruptive episodes.

Addressing Chronic Inflammatory Joint Pain and Stiffness

Agilex is relevant across therapeutic areas involving inflammatory or irritative processes that are commonly associated with persistent discomfort. It is used in situations involving symptomatic discomfort from rheumatoid arthritis and ankylosing spondylitis, and is applied in addressing symptoms related to chronic pain and morning stiffness. It helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Symptomatic Support

Indometacin is relevant for easing the overall symptom load, which assists with maintaining functional stability by managing symptoms related to physical discomfort, swelling, and tenderness associated with joint and soft tissue inflammation.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Agilex?

Agilex (Indometacin) eligibility is strictly defined by regulatory authorities based on absolute non-eligibility (contraindications) and patient risk status. Use is generally permitted for adults who do not possess any documented exclusions.


Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated and must not be used in the following populations:

  • Patients with a known hypersensitivity to Indometacin, or a history of allergic reactions, such as aspirin-sensitive asthma, after taking aspirin or other NSAIDs.
  • Women starting at 30 weeks gestation (third trimester of pregnancy).
  • Patients undergoing Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with active or a history of recurrent peptic ulcer or gastrointestinal hemorrhage.
  • Patients with severe heart failure, hepatic failure, or renal failure.

Age and Condition-Specific Eligibility Rules

  • Age-Related Eligibility: Safety and efficacy have not been established in children younger than 14 years of age. Use in older adults requires greater care due to increased risk of serious events.
  • Restricted Use: Use is not recommended for women who are breastfeeding. The medicine must be used with caution in patients with conditions like mild to moderate heart failure, uncontrolled hypertension, or pre-existing epilepsy or parkinsonism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Agilex (Indometacin) interacts with several medicinal products and substances, as documented in regulatory prescribing information. These interactions are classified based on their official outcome and required restrictions.

Formal Restrictions and Contraindications

Co-administration is formally contraindicated in patients with a history of allergic-type reactions, such as aspirin-sensitive asthma, to Aspirin or other NSAIDs. The medicine is also prohibited for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Pharmacodynamic and Exposure-Altering Interactions

Interaction Type Interacting Substance/Class Official Outcome
Increased Bleeding Risk Anticoagulants (e.g., Warfarin), Antiplatelet agents, SSRIs/SNRIs Additive pharmacodynamic risk of serious gastrointestinal bleeding.
Reduced Efficacy Antihypertensives (e.g., ACE Inhibitors, ARBs), Diuretics Diminution of blood pressure lowering and natriuretic effects.
Increased Exposure Lithium, Methotrexate Increased serum concentration and potential toxicity of the co-administered drug.

Population and Substance Notes

The use of alcohol is documented as a risk factor that significantly increases the risk of GI bleeding associated with Indometacin. Additionally, the risk of deterioration of renal function is heightened in elderly or volume-depleted patients when Indometacin is co-administered with ACE Inhibitors or ARBs.

Mechanism of Action

Primary Mechanism: Non-Selective Inhibition of Cyclooxygenase

The function of Agilex, which contains Indometacin, begins at the molecular level by acting as a non-selective inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By binding to and suppressing both COX isoforms, Indometacin blocks the initial, rate-limiting step in the cascade that converts arachidonic acid into prostaglandins (PGs). This modification of early molecular steps ultimately limits the proliferation of these key chemical mediators across multiple physiological systems.

Systemic Consequence: Modulating Central and Peripheral Signals

The suppression of PG production leads directly to defined physiological adjustments in two main areas. Peripherally, the reduced availability of PGs prevents the sensitization of pain-sensing nerve fibers (nociceptors). Centrally, the mechanism reduces Prostaglandin E2 ( PGE2) synthesis in the brain's hypothalamus, which is the physiological action required to reset the body's elevated temperature set point. These systemic effects lead to a dampening of both peripheral nociceptor sensitization and central thermal overactivity.

Dosage and Administration Information

How Agilex is Used

This section describes the administration and dosing patterns for Agilex (Indometacin), focusing on procedural usage principles and avoiding any clinical advice.


Administration Routes and Forms

Agilex is administered via the oral route (immediate-release capsules, extended-release capsules, and liquid suspension) and the rectal route (suppository). The oral suspension requires shaking well before measurement and consumption. Importantly, the extended-release capsules must not be crushed, broken, or chewed, as this compromises their intended delivery mechanism.


Standard Dosing Regimens

Dosing schedules are specific to the condition being managed. For chronic conditions like rheumatoid arthritis, the initial adult dose is typically 25 mg taken two or three times a day. The dose may be increased in increments of 25 mg or 50 mg weekly, up to a usual maximum total daily dose of 200 mg for immediate-release forms. For acute episodes, such as acute gouty arthritis, a higher dose of 50 mg three times a day is generally used, with the course rapidly reduced upon symptom relief.


Frequency and Contextual Use

Immediate-release oral forms are generally administered two to four times per day. The medicine should be taken with food to help minimize potential gastric distress. In chronic care, a portion of the dose, up to 100 mg, may be administered at bedtime to provide relief from night pain or morning stiffness. For older adults, the approach involves using the lowest effective dosage for the shortest duration possible due to increased sensitivity to the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Agilex


Evidence for Use in Acute Gouty Arthritis

Short-term Randomized Controlled Trials (RCTs) represent a core part of the evidence base related to acute gouty arthritis, which is a condition associated with acute or disruptive episodes. These studies were applied in populations of adults experiencing an acute inflammatory flare-up. Researchers examined outcomes related to physical discomfort, measuring factors like patient-reported pain intensity and objective signs like joint swelling over the course of the acute episode.

What remains uncertain is the scope of the evidence beyond the immediate, acute phase. Long-term outcomes that look beyond the initial flare event remain uncertain. Data for outcomes related to systemic or functional imbalance, such as the impact on future gout recurrence rates or chronic disease progression, are not typically documented in these acute trials.


Evidence for Symptomatic Relief in Chronic Joint Conditions

The evidence base includes studies where the medicine was studied in populations with established chronic joint conditions, such as Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). These research contexts involved various trial types, including RCTs. Studies monitored outcomes reflecting daily functioning or activity level, such as patient-reported pain, the duration of morning stiffness, and assessments related to mobility.

The research did not typically measure outcomes related to modification of the underlying chronic disease pathology or prevention of long-term structural joint damage. Data are limited regarding the persistence of symptomatic changes beyond the medium-term trials. Few contemporary data are available for specific subgroups defined by varying baseline disease severity.


Research Gaps and What Remains Uncertain

This section highlights areas where the evidence base for Agilex remains limited or where certainty remains low. A key limitation is that findings reflect the characteristics of the populations studied, and research describes group patterns, not personal outcomes.

Furthermore, sample sizes were modest in many acute studies, and comparative evidence is lacking in several areas. The existing studies provide limited insight into the ability of the medicine to modify the underlying course of a chronic condition. This research provides context but not individual predictions, emphasizing that evidence highlights what is known—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Agilex (FAQ)


Q: Does Agilex have a generic version available?

Yes, the active ingredient in Agilex, Indometacin, is available in generic form for some delivery types, such as the oral capsule or suspension. The availability of generic equivalents may vary based on the specific formulation of Agilex being prescribed and current regulatory approvals.


Q: Is Agilex the same type of medicine as [similar common drug name]?

Agilex contains Indometacin, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This means it belongs to the same general category of medicines as other common pain and inflammation relievers that are also classified as NSAIDs.


Q: How quickly does Agilex usually start working for people?

Official information indicates that for acute conditions, such as gout flare-ups, definite pain relief has typically been observed to occur within two to four hours after taking the medicine. Maximum relief of associated symptoms may take longer, often subsiding in 24 to 36 hours.


Q: Is it normal to feel a bit tired after starting Agilex?

Yes, regulatory documents report that side effects involving the central nervous system, including fatigue and somnolence (drowsiness), have been experienced by patients using Indometacin. If these effects are bothersome, information regarding them can be discussed with a healthcare professional.


Q: Can Agilex affect my mood or energy levels?

Official labeling reports that Indometacin has been associated with central nervous system effects. These reported adverse reactions have included changes in mood, such as depression and anxiety (which may involve nervousness), as well as fatigue.


Q: Is Agilex considered a long-term medication?

Regulatory guidance for this type of medicine often emphasizes that it should be used at the lowest effective dosage for the shortest duration possible. While it is used for chronic conditions, this approach is consistent with official recommendations for limiting exposure.


Q: Does Agilex cause weight changes?

Official regulatory documents list both weight gain and edema (the accumulation of excess fluid in body tissues), as reported adverse reactions associated with Indometacin.


Q: Is Agilex safe for people with high blood pressure?

Official warnings state that patients taking certain blood pressure medications, such as ACE inhibitors, may have a reduced response to those therapies when taking Indometacin. Regulatory advice recommends that blood pressure monitoring is appropriate while this medicine is being used.


Q: Are there any warnings about driving or operating machinery while on Agilex?

Official patient information advises that Indometacin may affect alertness, vision, or coordination. Patients are cautioned to avoid driving, operating machinery, or other potentially hazardous activities until they are aware of how the medicine affects them.


Q: Is Agilex addictive or habit-forming?

Agilex contains Indometacin, which is not classified as a controlled substance by regulatory agencies. It is not considered to be an addictive or habit-forming medicine.


Q: Does Agilex affect blood sugar levels?

Some medical research cited in authoritative literature has examined the effects of Indometacin on insulin secretion and glucose production. Individuals with blood sugar concerns can discuss this specific topic with a healthcare provider for clarification.


Q: What is the evidence regarding Agilex's use in pregnant individuals (descriptive)?

Data from studies during the first and second trimesters of pregnancy are described as inconclusive regarding the risk of birth defects. However, the medicine is strictly contraindicated starting at 30 weeks gestation (the third trimester) due to the risk of premature closure of a fetal heart vessel called the ductus arteriosus.


Q: What is the recommended maximum duration of use for Agilex, according to official sources?

Regulatory guidance recommends using the lowest effective dosage for the shortest possible duration. For acute conditions, such as acute gout, the total course of treatment is often limited to a period of 5 to 7 days.


Q: Are there any specific laboratory tests that need to be done while on Agilex?

Regulatory guidance advises that monitoring for changes in renal function (kidney health) and hepatotoxicity (liver damage) may be appropriate during treatment.


Q: Is Agilex a brand-new medication or has it been around for a while?

The active ingredient in Agilex, Indometacin, is not a brand-new drug. It was approved by the FDA prior to 1982 and is considered an established Nonsteroidal Anti-inflammatory Drug (NSAID) with a long history of use.


Q: How long does the effect of a single dose of Agilex last?

Pharmacokinetic data suggests that the time it takes for half of the dose to be cleared from the body (the half-life) is approximately 4.5 hours, though this can vary among individuals.


Q: Are there any known severe side effects associated with Agilex?

Official regulatory documentation highlights the potential for serious adverse events. These events include serious gastrointestinal problems (like bleeding or perforation) and cardiovascular thrombotic events (like heart attack or stroke), which require immediate attention.


Q: Can the effectiveness of Agilex be reduced by certain medicines?

Yes, official drug labeling confirms that the therapeutic efficacy of Indometacin can be diminished when co-administered with specific medicines. Examples include the blood pressure-lowering effects of certain diuretics (water pills) and ACE Inhibitors.


Q: Is there a patient brochure or official information sheet for Agilex?

The FDA requires that a specific Medication Guide, which is a patient-friendly information sheet detailing important safety information, must be provided to patients each time a prescription for an NSAID like Indometacin is dispensed.


Q: Why is Agilex sometimes prescribed for different conditions?

Agilex acts as a non-selective inhibitor of the COX enzymes, which are responsible for producing prostaglandins—the chemical mediators that cause pain, inflammation, and fever. Because its mechanism targets these general pathways, it is suitable for addressing symptoms across multiple inflammatory conditions.


Q: Can older adults typically use Agilex?

Older adults can use Agilex, but official guidance emphasizes that use in this population involves using the lowest effective dose for the shortest duration due to increased risk of serious gastrointestinal and kidney-related adverse events.

How should Agilex be stored and disposed of?

How to Store and Dispose of Agilex?

Agilex (Indometacin) must be stored and disposed of according to the official requirements for the active ingredient, ensuring product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store capsules at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Moisture The oral suspension must be protected from moisture and kept in a tightly closed container.
Stability Discard the oral suspension after 30 days of initial mixing or reconstitution.
Safety Keep the medicine out of the reach of children.

Disposal Instructions

Do not flush unused or expired Agilex down the toilet or pour it into a drain. The regulatory standard requires disposal through an official drug take-back program or by following local guidelines provided by the pharmacist or healthcare waste authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Agilex found in:

A-Z Index: